|
| Wednesday, January 25, 2017 |
|
|
Phase III Trial of Anticancer Agent Lenvima as First-Line Treatment for Unresectable Hepatocellular Carcinoma Meets Primary Endpoint |
| Eisai Co., Ltd. announced today that a Phase III clinical trial of its in-house discovered and developed anticancer agent Lenvima against the comparator sorafenib as a first-line treatment for patients with unresectable hepatocellular carcinoma has achieved its primary endpoint. more info >> |
|
| Tuesday, January 24, 2017 |
|
|
Eisai Selected for Excellence in Sustainability Performance and Industry Mover Distinction by Robecosam |
| Eisai Co., Ltd. announced today that it has been selected for excellence in sustainability performance by RobecoSAM AG, a leading assessor of Social Responsibility Investment (SRI). more info >> |
|
| Wednesday, January 18, 2017 |
|
|
Eisai to Participate in Access Accelerated, Global Partnership to Address Rise of Non-Communicable Diseases |
| Eisai Co., Ltd. announced today that it is participating in Access Accelerated, a global partnership to advance access to non-communicable diseases (NCDs) prevention, treatment and care in low and lower-middle income countries. more info >> |
|
| Monday, January 16, 2017 |
|
|
Transfer of Rights to Insomia Treatment / Anaesthesia Induction Agent Flunitrazepam in Japan |
| Eisai Co., Ltd. and Chugai Pharmaceutical Co., Ltd. announced today that Eisai's aquisition of the rights for manufacturing active pharmaceutical ingredients for Japan from F. Hoffman-La Roche Ltd. for the insomnia treatment / anaesthesia induction agent flunitrazepam. more info >> |
|
| Thursday, January 12, 2017 |
|
|
Eisai to Launch Medication Administration Support Device |
| Eisai Co., Ltd. has announced that the medication administration support device e-OKUSURI-SAN will be launched today for sale to pharmacies, medical institutions and caregiving facilities in Japan. more info >> |
|
| Thursday, January 5, 2017 |
|
|
Eisai Acquires All Global Development and Marketing Rights for Chronic Weight Management Treatment Lorcaserin |
| Eisai Co., Ltd. announced today that, in association with its U.S. pharmaceutical subsidiary Eisai Inc., it has reached an agreement with Arena Pharmaceuticals, Inc. to revise the November 2013 marketing and supply agreement it concluded with Arena's wholly owned subsidiary, Arena Pharmaceuticals GmbH, for the chronic weight management treatment lorcaserin hydrochloride. more info >> |
|
| Thursday, December 22, 2016 |
|
|
Eisai and Keio University to Establish a New Industry-Academia Collaboration Site |
| Eisai Co., Ltd. and Keio University announced today that they have entered into a new joint research agreement for the discovery and development of new drugs targeting dementia. more info >> |
|
| Tuesday, December 20, 2016 |
|
|
Anticancer Agent Treakisym Approved in Japan for Additional Indication as First-Line Treatment for Low-Grade B-Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma |
| Eisai Co., Ltd. announced today that the anticancer agent TREAKISYM (generic name: bendamustine hydrochloride) has been approved in Japan for an additional indication as first-line treatment for low-grade B-cell non-Hodgkin's lymphoma and mantle cell lymphoma (MCL). more info >> |
|
| Friday, November 18, 2016 |
|
|
U.S. FDA Grants Fast Track Designation for the Development of Eisai's Bace Inhibitor E2609 for Early Alzheimer's Disease |
| Eisai Co., Ltd. announced today that the U.S. FDA has granted Fast Track designation for the development of the beta secretase cleaving enzyme (BACE) inhibitor E2609 which was discovered by Eisai and is being jointly developed by Eisai and Biogen Inc. more info >> |
|
| Friday, November 4, 2016 |
|
|
U.K. NICE Recommends Anticancer Agent Halaven as Treatment for Advanced Breast Cancer |
| Eisai Co., announced today that its in-house developed anticancer agent Halaven has been recommended by the U.K. National Institute for Health and Clinical Excellence (NICE) as a treatment for patients with locally advanced or metastatic breast cancer who have received at least two chemotherapeutic regimens for advanced disease in NICE's Final Appraisal Determination (FAD). more info >> |
|
|
|
